Drug Profile
Research programme: cancer therapeutics - Piramal Healthcare
Alternative Names: Microbial leads - Piramal Healthcare; PI3 kinase - Piramal HealthcareLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Piramal Healthcare
- Developer Piramal Enterprises
- Class
- Mechanism of Action 1 Phosphatidylinositol 3 kinase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in India (PO, Tablet)
- 01 Jan 2008 Early research in Cancer in India (unspecified route)